Drugs / CM383
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07292688 | Jan → Jul 2026 overdue | — | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06619613 | Nov 2024 → Dec 2026 expected | Alzheimer disease | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06412185 | May 2024 → Jun 2025 | Alzheimer disease | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM383 | “CM383 injection” NCT06619613 ↗ |
| Route | Intravenous | “CM383 injection and matched placebo, intravenous injection” NCT06412185 ↗ |